Incyte Corporation - Common Stock (NQ:INCY)

113.31 -2.40 (-2.07%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Incyte Highlights Promising Early Data for ’890 and ’734 in GI Cancers ↗

October 26, 2026

Incyte (NASDAQ:INCY) presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “’890,”...

Via MarketBeat

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

October 26, 2026

From Incyte

Via Business Wire

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

October 24, 2026

From Genmab A/S

Via Business Wire

Discover the top S&P500 movers in Monday's after-hours session. ↗

October 12, 2026

Via Chartmill

Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup ↗

September 30, 2026

Via Chartmill

Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum ↗

September 18, 2026

Via Chartmill

Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup ↗

September 08, 2026

Via Chartmill

Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience ↗

August 27, 2026

Via Chartmill

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

October 24, 2026

From Incyte

Via Business Wire

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

October 18, 2026

From Incyte

Via Business Wire

2 High-Flying Stocks with Competitive Advantages and 1 We Question

October 16, 2026

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...

Via StockStory

Incyte to Report Third Quarter Financial Results

October 08, 2026

From Incyte

Via Business Wire

Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup ↗

August 17, 2026

Via Chartmill

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment

September 30, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

Via StockStory

Topics Artificial Intelligence

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

September 25, 2026

From Mirum Pharmaceuticals, Inc. and Incyte

Via Business Wire

Discover the top S&P500 movers in Tuesday's pre-market session. ↗

September 22, 2026

Via Chartmill

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

September 22, 2026

From Incyte

Via Business Wire

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target ↗

September 19, 2026

Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after...

Via MarketBeat

3 Growth Stocks to Add to Your Roster

September 17, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

Topics Economy

1 Cash-Heavy Stock for Long-Term Investors and 2 We Ignore

September 16, 2026

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...

Via StockStory

Topics Credit Cards

Incyte (INCY): 3 Reasons We Love This Stock

September 14, 2026

Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks ...

Via StockStory

Topics Artificial Intelligence Stocks

Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today ↗

September 11, 2026

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of...

Via Benzinga

2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off

September 11, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

3 Market-Beating Stocks with Competitive Advantages

September 09, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off

September 04, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

Incyte to Present at Upcoming Investor Conferences

September 01, 2026

From Incyte

Via Business Wire

Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years ↗

August 20, 2026

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of...

Via Benzinga

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 07, 2026

From Incyte Corporation

Via Business Wire

July 31, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Topics Supply Chain

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

July 29, 2026

From Incyte

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.